Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00549510 · ClinicalTrials.gov registry record · Phase 1

Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.

A Phase 1 study, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 1
Development phase
29
Enrollment target

NCT00549510: Completed Phase 1 study, sponsored by GlaxoSmithKline.

NCT00549510 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 29 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00549510, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 1
Development phase
29 participants
Enrollment target

Study Summary

This will be an open-label, single-dose, non-randomized, five-period crossover study in healthy volunteers. The duration of the study will last up to eleven weeks from screening to follow-up. PK samples will be taken.

Interventions

  • DRUG COREG CR and lisinopril (FDC)

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2007-10
Est. Completion 2007-12
Phase Phase 1
GlaxoSmithKline

1,345 total trials

What the finished NCT00549510 record still lists

NCT00549510 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower).

The record links to 0 conditions, and to 1 intervention - of which COREG CR and lisinopril (FDC) is the first listed.

NCT00549510 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00549510 about?

NCT00549510 is a clinical study titled "Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.". This will be an open-label, single-dose, non-randomized, five-period crossover study in healthy volunteers. The duration of the study will last up to eleven weeks from screening to follow-up. PK samples will be taken.

What is the current status of trial NCT00549510?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2007-10. Estimated completion is 2007-12.

What interventions are being tested in trial NCT00549510?

The interventions under investigation include: COREG CR and lisinopril (FDC) (DRUG).

Who is sponsoring clinical trial NCT00549510?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00549510's enrollment target sits among peer trials

29 1440th of 2000 higher than 554 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02429557 · 29 participants · Phase 1

    Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure

  • NCT02568878 · 29 participants · Phase 3

    Creatine for Depressed Male and Female Methamphetamine Users

  • NCT03014401 · 29 participants · NA

    The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis

  • NCT03128996 · 29 participants · Phase 1

    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00549510, the US trial registry maintained by the National Library of Medicine. NCT00549510 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.